Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration

Purpose To analyze the value of novel measures of retinal pigment epithelium–drusen complex (RPEDC) volume to predict 2-year disease progression of intermediate age-related macular degeneration (AMD). Design Prospective, observational study. Participants Three hundred forty-five AMD and 122 non-AMD...

Full description

Saved in:
Bibliographic Details
Published inOphthalmology (Rochester, Minn.) Vol. 123; no. 1; pp. 39 - 50.e1
Main Authors Folgar, Francisco A., MD, Yuan, Eric L., BSE, Sevilla, Monica B., MS, Chiu, Stephanie J., PhD, Farsiu, Sina, PhD, Chew, Emily Y., MD, Toth, Cynthia A., MD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose To analyze the value of novel measures of retinal pigment epithelium–drusen complex (RPEDC) volume to predict 2-year disease progression of intermediate age-related macular degeneration (AMD). Design Prospective, observational study. Participants Three hundred forty-five AMD and 122 non-AMD participants enrolled in the Age Related Eye Disease Study 2 Ancillary Spectral-Domain (SD) Optical Coherence Tomography (OCT) study. Methods High-density SD OCT macular volumes were obtained at yearly study visits. The RPEDC abnormal thickening (henceforth, OCT drusen) and RPEDC abnormal thinning (RAT) volumes were generated by semiautomated segmentation of total RPEDC within a 5-mm-diameter macular field. Main Outcome Measures Volume change and odds ratio (OR) with 95% confidence intervals (CI) for progression to advanced AMD with choroidal neovascularization (CNV) or central geographic atrophy (GA). Results Complete volumes were obtained in 265 and 266 AMD eyes and in 115 and 97 control eyes at baseline and at year 2, respectively. In AMD eyes, mean (standard deviation) OCT drusen volume increased from 0.08 mm3 (0.16 mm3 ) to 0.10 mm3 (0.23 mm3 ; P < 0.001), and RAT volume increased from 8.3 × 10−4 mm3 (20.8 × 10−4 mm3 ) to 18.4 × 10−4 mm3 (46.6 × 10−4 mm3 ; P < 0.001). Greater baseline OCT drusen volume was associated with 2-year progression to CNV ( P  = 0.002). Odds of developing CNV increased by 31% for every 0.1-mm3 increase in baseline OCT drusen volume (OR, 1.31; 95% CI, 1.06–1.63; P  = 0.013). Greater baseline RAT volume was associated with significant 2-year increase in RAT volume ( P < 0.001), noncentral GA ( P < 0.001), and progression to central GA ( P < 0.001). Odds of developing central GA increased by 32% for every 0.001-mm3 increase in baseline RAT volume (OR, 1.32; 95% CI, 1.14–1.53; P < 0.001). In non-AMD eyes, all volumes were significantly lower than AMD eyes and showed no significant 2-year change. Conclusions Macular OCT drusen and RAT volumes increased significantly in AMD eyes over 2 years. These quantitative SD OCT biomarkers predict 2-year AMD progression and may serve as useful biomarkers for future clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
ISSN:0161-6420
1549-4713
DOI:10.1016/j.ophtha.2015.09.016